The illusions and delusions of screening for cancer.
“The largest threat posed by American medicine is that more and more of us are being drawn into the system not because of an epidemic of disease, but because of an epidemic of diagnoses. The real problem with the epidemic of diagnoses is that it leads to an epidemic of treatments. Not all treatments have important benefits, but almost all can have harms” 1
Introduction
A couple of weeks ago I was showing off my newly acquired iPhone to my very bright 12-year-old granddaughter when she elected to “Google” my name. To my amazement the top hit appeared to link my name with that of Jade Goody. As far as I could recall I had never met with her, I have never knowingly watched Big Brother and I don’t even research or treat cervical cancer. It appears that I was being stigmatized as the leading anti-screening dinosaur. Everything became clear when on Monday the 23rd March 2009, the Times published a full- page obituary on the short and tragic life of the reality TV celebrity, Jade Goody, whose dying wish was that women under the age of 25 should have access to screening for cervical cancer. The “Goody effect” has already provoked a campaign and a response from the department of health. I have nothing against the late Jade, in fact she reminded me of the type of patient that used to make my NHS clinics in central London such fun.
Nevertheless I feel the urge to defend myself and to explain why being a screening sceptic might after all place on the side of the angels rather than to the darker side of Darth Vader. For a start I must hasten to mention that some of my best friends are women. My beloved mother died of breast cancer and my equally beloved sister is a long- term survivor of the disease. Galvanized by this experience I’ve devoted my whole professional life to fighting breast cancer, visualizing it as a slavering beast and in moments of self-delusion seeing myself as St. Michael. My wife’s reminder, that this brand name is sewn in the back of my underpants, tends to bring me down to earth.
In addition I actually know a thing or two about screening. In 1987 when I was employed as Professor of Surgery at Kings College Hospital, I was commissioned by the DoH to establish the first breast-screening unit following the publication of the Forrest report. This unit was built near Camberwell Green in South East London and served as the training centre for the South-East of England. Furthermore for the last 8 years I’ve acted as the chairman of the National trial to evaluate PSA screening for the early detection of prostate cancer.
Suddenly a confluence of events has thrown the subject of screening for cancer into the public eye again. To start with there was the publication of the Nordic Cochrane centre on mammographic screening in the BMJ in February 20092 along with an open letter to the Times signed by me amongst 27 other experts, both of which provoked a debate on the wisdom of screening for breast cancer. Then there were two papers published in the New England Journal of Medicine in March, reporting on the early results of screening for prostate cancer by using the PSA blood test.3,4 This was accompanied by banner headlines in the Daily Telegraph demanding PSA screening on the NHS that could save 2,000 lives a year. Later on I will explain just how wrong this statement was but before then it behoves me to explain some of the delusions and illusions of screening in general.
“For every complex problem there is a simple solution-and it’s wrong”5
The majority of lay people could be forgiven for believing that one of the mainstays in the fight against cancer is “early detection”. This belief has generated a European wide consensus that screening for cancer before it becomes symptomatic will save lives. It has also become the main plank in the government’s campaign to improve cancer survival in the UK to match the highest levels achieved in the EU. In the vanguard of this campaign, the NHS screening programme for breast cancer (NHSBSP) by mammography has been lauded as a triumph and has laid claim to the responsibility for the dramatic decline in breast cancer mortality since its initiation more than 20 years ago. Those of us who have remained sceptical from the start have been branded as either misogynists or fools. Furthermore if its good enough for women, what about men’s health as well? How can early detection of cancer be a bad thing? Although counterintuitive, a growing body of informed opinion is moving in that direction.
Biases of screening that can disguise the truth and the diagnosis of “pseudo-cancers”.
Let us start by considering two separate but related issues; firstly biases of screening that give a false impression of benefit and secondly the over-detection of cancer “look-alikes” that if left undetected might never threaten a patient’s life. The survival from cancer is measured from the time of detection until recurrence and death. If a frame shift in the chronology of the disease due to screening occurs, then survival is automatically extended even if the ultimate outcome is the same; this is called lead-time bias. Of course if the “cancer” detected would never have threatened a woman’s life in the first instance then that lead time might be as long as 30 years. Next, bearing in mind that the interval between screens is anything from one to three years, it is inevitable that the fast growing tumours with a bad prognosis will appear during the intervals whilst the slow growing tumours with a good prognosis will sit around until found by mammography; this is called length bias. There is also another subtle bias that can be described as the “self selection” bias. In that women who accept invitations for screening might be demographically different to those who ignore the invitation. For a variety of reasons such women have better outcomes in the treatment of cancer forgetting whether they were screen detected or not. The only way to account for these biases is to consider all the clinical trials of screening versus no screening and look for the pooled results described in terms of mortality i.e. the number of women dying in the screened group compared with those dying in the control group rather than case survival. There is in fact a modest advantage to screening looked upon in those terms, as described in the recent publication in the BMJ; “Breast screening: the facts—or maybe not” by Peter C Gøtzsche and his colleagues from the influential and independent, Nordic Cochrane Centre.2
In this milestone paper they describe a synthesis of all the papers that describe both the benefits and harms of screening using absolute rather than relative numbers that make easy for women comprehend and conclude as follows. If 2000 women are screened regularly for 10 years, one will benefit from the screening, as she will avoid dying from breast cancer. (The U.S.Preventive Services Task Force derived a similar number independently in 2004.6 ) However even the 1:2,000 might be an over-estimate. Remember these data were derived from the trials that were mostly started in the 1970s and reported in the late 1980s. Since then improvements in treatment, such as the adoption of tamoxifen and adjuvant chemotherapy, have narrowed the window of opportunity and we have witnessed a drop in mortality of 30%- 40% both in the age group that are invited for screening (>50) as well as for the younger woman. So perhaps the correct number might be 1:2,000 X 0.6, i.e.1:3,000
Forgetting the precise number, that one woman who benefits from a decade of screening has a life of infinite worth and if screening were as non-toxic as wearing a seat belt there would be no case to answer. However there is a downside and that is the problem of the over-diagnosis of “pseudo-cancers”. It is deduced by the Cochrane report that for every life saved10 healthy women will, as a consequence, become cancer patients and will be treated unnecessarily. These women will have either a part of their breast or the whole breast removed, and they will often receive radiotherapy and sometimes chemotherapy. This is the tricky part of the story that is more or less denied by the screening fraternity and therefore deserves some close attention.
An explanation for, and the nature of, the over-diagnosed cancers
Screening for breast cancer is now adopted as an unequivocal good by most of the members of the EU. Invitations for screening promote this activity by being economical with the truth.7 One of the uncomfortable truths concerns the over-diagnosis of both in-situ and invasive breast cancers in screening populations.8 Over-diagnosis of breast cancer doesn’t mean false positive rates but the detection and treatment of cancers that left undetected would never threaten a woman’s life and with which she would live, in blissful unawareness until she died naturally of old age. We had always assumed that there was an over-diagnosis of duct carcinoma in-situ (DCIS), some of which had the potential of progressing to an invasive and life-threatening phenotype. However, there is now clear evidence that anything between 10% and 50% of invasive cancers detected and treated radically as a result of screening, would never threaten life.9 As a result the overall mastectomy rate rises after any country implements screening in contrast to the message in the NHSBSP leaflet, “breast cancer the facts” 10 that implies that screening saves breasts. It doesn't.
How can this possibly be? Don’t we know that if cancer is neglected it will progress to a life threatening condition?
By way of illumination let me propose that the pathological diagnosis of cancer at screening is based on a syllogism; (a syllogism is a logical argument in three propositions, two premises and a conclusion, the conclusion being specious) A simple example might be that people who die from meningitis, harbour meningococci in their nose. This does not mean that harbouring meningococci in the nose is a lethal condition, in fact about 10% of the population harbour these bacteria. Cancer was defined by its microscopic appearance about two hundred years ago. The 19th century saw the birth of scientific oncology with the discovery and use of the modern microscope. Rudolf Virchow, often called the founder of cellular pathology, provided the scientific basis for the modern pathologic study of cancer. As earlier generations had correlated the autopsy findings observed with the unaided eye with the clinical course of cancer one hundred years earlier, so Virchow correlated the microscopic pathology of the disease.
However the material he was studying came from the autopsy of patients dying from cancer. In the mid 19thC pathological correlations were performed on living subjects presenting with locally advanced or metastatic disease that almost always were pre-determined to die in the absence of effective therapy. Since then without pause for thought, the microscopic identification of cancer according to these classic criteria has been associated with the assumed prognosis of a fatal disease if left untreated. The syllogism at the heart of the diagnosis of cancer therefore runs like this; people frequently die from malignant disease, under the microscope this malignant disease has many histological features we will call “cancer”, ergo anything that looks like “cancer” under the microscope, will kill you. I would therefore like to argue that some of these earliest stages of “cancer” if left unperturbed, would not progress to a disease with lethal potential. These “pseudo-cancers” might have microscopic similarity to true cancers but these appearances are only a necessary rather than sufficient condition for a fatal disease. I would also like to suggest that many of the “risk factors” for the development of cancer are in fact the promotional agents of a latent condition that Welch has described as pseudo-cancers1. If we stand back at take a broader look at nature this shouldn’t be surprising. Conventional mathematical models of cancer growth are linear or logarithmic, in other words completely predictable at the outset. These mathematical formulae may be appropriate for designing theme park rides but cannot begin to explain the exquisite organization of cell proliferation and the complex inter-relationships of cells of different progeny.
Most natural biological mechanisms are non-linear or better described according to chaos theory. The beauty of the tree in full leaf is reflects its fractal geometry that looks remarkably similar to the microscopic appearance of the mammary ducts and lobules under the microscope. The rate of growth and the development of the lung along with the fingers and toes in the foetus, cannot be described in linear terms. Wound healing starts with the knife and ends when it needs to, although rarely wound healing carries on too long to leave an ugly keloid scar. Prolonged latency followed by catastrophe should not be all that surprising. We accept the case for prostate cancer, as we know that most elderly men will die with prostate cancer in situ and not of prostate cancer that has invaded. In fact the UK national PSA screening trial is predicated on that fact with two a priori outcome measures defined, deaths from prostate cancer versus the number of cancers treated unnecessarily. Why oh why does the breast cancer lobby remain in denial? Of course now that the cat is out the bag they will have no choice but to include this fact in their invitations in order to avoid litigation from an irate woman in the future. Furthermore “the sins of the mother are visited on the daughter”. We now have cases of women with screen detected DCIS whose daughters have had problems raising mortgages when the insurers have discovered this family history of breast cancer! 11,12 However even the concession by the DoH on this fact, as reported in the Times, only acknowledges one cancer over-diagnosed for every life saved. How on earth do they derive that number? The Cochrane report is transparent on this matter and the numbers are there for all to see. They simply record the numbers of breast cancers that have appeared in the screened group (observed) and subtracted the numbers expected as seen in the unscreened control populations in the trials that have now been followed up for the majority of these women’s lifetimes.
(Observed-expected = over-diagnosis) How the DoH arrived at the figure of one to one is therefore inexplicable. The charitable conclusion is that they were caught off guard and trotted out the figures that are 10 years out of date rather than being guilty of a “dodgy dossier”.
Prostate cancer
By way of a minor diversion I want briefly to mention prostate cancer screening. In my preamble I mentioned the banner headlines in one of our respected broadsheets following the publications in the New England Journal of Medicine in March 2009.3,4 Well unlike the writers of that piece I actually read the publications and not just the press release of a prostate cancer charity. There were in fact two studies reported together with a lengthy editorial. The first study was American and produced a negative result. The larger European study was of borderline statistical significance and for the statistically literate amongst you, showed a 20% relative risk reduction of cancer specific mortality over a 10 year period with a p value of <0.04. Never mind the stats, translated into numbers that all lay men could understand, you would need to screen 1,400 men for 10 years to save one prostate cancer death at the expense of over-diagnosing 48 cases of cancer that would be treated with radical surgery that frequently lead to impotence and incontinence and on rare occasions death from the complications of surgery. The editorial concluded that it was premature to make any kind of recommendation and urged that we waited for the outcome of the British trial. That happens to be the study I chair. I can claim no credit for the elegant and ambitious design of that trial that is all down to the three principle investigators, Freddie Hamdy, Jenny Donovan and David Neal. I was invited in as an independent chairman to see fair play. 500,000 men in the UK have been randomized to PSA screening or not. Those with a raised PSA are further investigated and if in the end their prostate biopsies showed localized cancer they are then offered re-randomization to three treatment groups, radical surgery, radical radiotherapy or “active monitoring”. The two primary outcome measures are cancer specific mortality and the rate of over-diagnosis. Health economics is factored in as well and the secondary randomization will allow measures of quality of life as well as length of life in the different treatment groups, whilst the “active monitoring” arm will allow us to study the natural history of screen detected prostate cancer. This latter group will also allow us to study the molecular biology of the disease to see if we can learn to separate out the “poodles” (cancers that will remain latent for the duration of life) from the “Rottweiler’s” (those that are predetermined to invade and spread). If only we had our time over again that is how the breast cancer trials should have been designed!
Is there a reasonable “exit strategy”?
Let me summarize in a series of bullet points where we have arrived with breast cancer screening.
• The current NHS screening programme is based on the results of randomized controlled trials that were published before 1987 and started in the late 1960s and early 1970s
• Some of these trials in retrospect were of poor quality
• With mature follow up, careful attention to biases a relative risk reduction (RRR) in breast cancer specific mortality has been estimated as 15%
• In absolute terms therefore the numbers needed to screen over 10 years to prevent one breast cancer death is about 1:2,000. Anything better than this depends on ignoring the obvious biases in the trials, mathematical manipulation of the data that I either simply don’t understand or is based on those self -selected women who accept the invitation to screen. (“Selection bias”)
• Along the way the estimates of harm have increased. At the outset the hazards of over-diagnosis were ignored, then as the rate of screen detected duct carcinoma in situ (DCIS) shot up it was still judged to be worth the cost. Now we recognize that the over-diagnosis of invasive cancers (IDC) that are not predestined to threaten a woman’s life is a problem. The extent of over-diagnosis is debateable but I personally agree that if you include DCIS and IDC it mounts to about 10 cases treated unnecessarily for every life saved.
• Putting politics aside for the moment I wonder how many of us would have voted for the NHSBSP in 1987 knowing what we know today.
• Furthermore in spite of the wonderful advances we’ve made in imaging technology and treatment in the last 20 years there has been only one new trial reported for screening and that was the trial for the under 50s that supported the 15% estimate.13
• In other words we are using state of the art imaging and modern therapy to service a programme based on data that is 20 years old. It is also worth re-iterating at this juncture that improvements in the treatment of symptomatic patients since the mid 1980s leaves a much narrower window of opportunity for screening so that even our estimates of 1: 2,000 based on these old trials might have to be multiplied by a factor of about 0.6.
• So where do we go from here? To close the programme is politically unacceptable. I therefore want to make two practical propositions for research and development. One concerns “person preferences” and the other concerns the more efficient use of scarce resources that I will refer to as risk assessment/risk management (RARM)
Person preference
Since 1997 when I resigned from the NHSBS committee I have publically expressed my concerns on the issue of informed choice for women invited for screening. This has often led to ridicule and ad hominum attacks. I take no particular pleasure in the fact that NHS has at last accepted the point and agreed to rewrite the letters of invitation.
From The Times February 21, 2009
“NHS rips up breast cancer leaflet and starts all over again”
My concern is that they will repeat the mistakes of the past if we leave this task to the usual suspects. Furthermore it’s not for me to prejudge what level of benefit and what level of harm might influence the average woman to accept the invitation. For this reason I think there are two related areas of research. First the development of an information pack that includes decision aids. This could be used in a person preference study where well women might be offered sliding scales of benefits and harms to find the point at which screening is judged acceptable. These data might then inform the next and perhaps more important area of research on more efficient ways of using scarce resources in the NHS.
RARM
The beauty of a risk assessment risk management is that it provides a platform for the management of all women in an attempt to reduce the mortality from breast cancer where mammographic screening is one component of an integrated programme. The first step is to set up a facility nation wide for risk assessment using one of the modern computer programmes. Women would then be offered not compelled to accept this service. Initially a practice nurse could administer this questionnaire but it would be quite easy to transfer this to a web- based programme for the computer literate members of the community. From the read-out an initial triage could be agreed. Those at the most extreme end of the risk spectrum, say with a relative risk (RR) of say >10.0, could be invited to a clinical genetics consultation. At the other extreme those with a RR of say <2.0 might be reassured and given lifestyle advise on diet, alcohol and exercise. (Please note that these risk ratios are for illustration only, the actual figures used could be derived from the person preference studies and the cut off for genetic counselling is already broadly accepted) Those in between could then be invited to a special clinic for the second step. At this clinic women of 45 or older could have a mammogram to determine breast density that might also be kept as a baseline but also provide additional evidence about risk. (The greater the mammographic density the higher the risk) Those with radiological abnormality at this stage would be investigated in the accepted way. If the mammographic density is low and the repeat estimate falls below a RR of 2.0 then they would be reassured and given lifestyle advise. Those that remain with a RR 2.0-10.0 would be offered screening. In addition those who were pre-menopausal might be offered prevention with tamoxifen and those who were post-menopausal could be offered entry into the IBIS II trial, a study comparing tamoxifen with arimidex for the chemo-prophylaxis of breast cancer). A recent paper in JNCI supports the validity of this approach.14
Conclusion
To carry on regardless is no longer acceptable neither is political spin the answer. Women are now getting smarter and the demand for change doesn’t just come from grumpy old men like me but also from the legions of wise women represented by the signatories of the letter in the Times. However the changes I have in mind are not destructive but constructive. The NHSBSP has indirectly lead to the provision of the best specialist services for the diagnosis and treatment of symptomatic breast cancer in the world, riding on the back of the screening units. The centralization of care has lead to the rapid recruitment into RCTs for the treatment of cancer that is the major contributor to the dramatic fall in breast cancer mortality in the UK over the last two decades. If we can now add to this the prevention of the disease and a risk adjusted screening programme then everyone is a winner.
References
[1] What’s Making Us Sick Is an Epidemic of Diagnoses
H. GILBERT WELCH, LISA SCHWARTZ and STEVEN WOLOSHIN
The New York Times, January 2, 2007
[2] “Breast screening: the facts—or maybe not”, Gøtzsche PC et al
BMJ 2009, 338; 446-448
[3] Mortality results from a randomized prostate screening trial. Andriole et al. NEJM 2009, 360: 1310-1319
[4] Screening and prostate cancer mortality in a randomized European trial.
Schroder et al NEJM 2009, 360:1320-1328
[5] Aphorism of American humorist H.L. Menken
[6] U.S.Preventive Services Task Force. Screening for Breast Cancer: Recommendations and Rationale. Ann Intern Med 2002;137: 344-6.
[7] Screening and choice: Informed choice for screening: implications for evaluation. Les Irwig, Kirsten McCaffery, Glenn Salkeld, Patrick Bossuyt: BMJ 2006;332:1148-1150,
[8] Rate of over-diagnosis of breast cancer 15 years after end of Malmö mammographic screening trial: follow up study. Zackrisson S, Andersson I, Manjer J and Garne JP, BMJ 2006;332:689-92
[9] “Should I be tested for Cancer?” H.Gilbert Welch
University of California Press, 2004, ISBN 0520239768
[10] Incidence of breast cancer in Norway and Sweden during introduction of nationwide screening: prospective cohort study. Zahl PH, Strand BH, Maehlen J. BMJ. 2004 Apr 17;328(7445):921-4.
[11] “Randomised Clinical Trials: the patient`s point of view.” Hazel Thornton,
in Ductal Carcinoma in Situ of the Breast. Ed. Melvin Silverstein. Williams and Wilkins 1997.
[12] Insurance repercussions of mammographic screening: What do women think? Claire Davey, Victoria White, Jenette E. Ward. Medical Science Monitor 2003; 8:LE44-45
[13] Effect of mammographic screening from age 40 years on breast cancer mortality at 10 years’ follow up: a randomised controlled trial. Moss SM, Cuckle H, Evans A, Johns L, Waller M, Bobrow L, The Lancet 2006, 368; 2053-2060
[14] Prevention of Breast Cancer in Postmenopausal Women: Approaches to Estimating and Reducing Risk: Steven R. Cummings, Jeffrey A. Tice, Scott Bauer, Warren S. Browne, Jack Cuzick et al; J Natl Cancer Inst 2009;101:
384 – 398
Wednesday, 1 April 2009
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment